Skip to main content

Table 1 Characteristics of Patients at Baseline

From: Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up

 

Stage 1 (n = 181)

Advanced (n = 77)

Median age, years (range)

36 (14–64)

38 (14–61)

Initial clinical staging, n (%)

Localised

184 (100)

15 (19)

Advanced

-

62 (81)

Surgical management, n (%)

Orchidectomy

184 (100)

71 (92)

Retroperitoneal lymph node dissection

-

2 (3)

Other surgery (metastectomy)

-

2 (3)

Adjuvant therapy for stage 1 seminoma, n (%)

Chemotherapy

33 (18)

3 (20)*

Radiation therapy

82 (45)

3 (20)*

None

63 (34)

9 (60)*

Unknown

6 (3)

0 (0)*

Treatment(s) for advanced/recurrent testicular seminoma, n (%)

Chemotherapy

-

43 (56)

Radiation therapy

-

40 (52)

Surgery

-

4 (5)

Number of FDG-PET/CT per patient, n (range)

1 (1–3)

2 (1–7)

Median follow-up from initial diagnosis with seminoma, years (range)

6.4 (0–17)

9.3 (0–25)

  1. *Of 15 individuals originally diagnosed with stage 1 seminoma and eligible for adjuvant treatment